Table 3.

Summary of rivastigmine clinical trials

Study	No. of Pts	Study duration (wks)	Dosage (mg/day)	Results (%) at week 26 vs Baseline
				ADAS-cog	CIBIC-plus	MMSE
Agid et al 1998	402	13	Placebo	Not done	29.9a	0.0
			4	Not done	31.5	0.0
			6	Not done	42.7	0.3
Corey-Bloom et al 1998	699	26	Placebo	4.15	4.39	−0.79
			1–4	2.27	4.23b	−0.33
			6–12	−0.79c	4.20d	0.30b
Rosler et al 1999	725	26	Placebo	1.34	4.38	−0.47
			1–4	1.37	4.24	−0.62
			6–12	−0.26b	3.91d	0.21b

Notes: ^asubjects scored 1 or 2;

^bp < 0.05;

^cp < 0.001;

^dp < 0.01.

Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale–Cognitive section; CIBIC-plus, Clinician Interview-Based Impression of Change-plus; MMSE, Mini Mental State Examination; Pts, patients.